You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 8, 2024

Investigational Drug Information for Radium-223


✉ Email this page to a colleague

« Back to Dashboard


What is the development status for investigational drug Radium-223?

Radium-223 is an investigational drug.

There have been 79 clinical trials for Radium-223. The most recent clinical trial was a Phase 3 trial, which was initiated on November 9th 2020.

The most common disease conditions in clinical trials are Prostatic Neoplasms, Neoplasm Metastasis, and Carcinoma. The leading clinical trial sponsors are Bayer, National Cancer Institute (NCI), and Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.

There are one hundred and seven US patents protecting this investigational drug and zero international patents.

Recent Clinical Trials for Radium-223
TitleSponsorPhase
Darolutamide With Radium-223 or Placebo and the Effect on Radiological Progression-Free Survival for Patients With mCSPCBayerPhase 3
Darolutamide With Radium-223 or Placebo and the Effect on Radiological Progression-Free Survival for Patients With mCSPCGenesisCare USAPhase 3
Combination of Radium-223 and Lutetium-177 PSMA-I&T in Men With Metastatic Castration-Resistant Prostate Cancer: Phase I/II StudyPeter MacCallum Cancer Centre, AustraliaPhase 1/Phase 2

See all Radium-223 clinical trials

Clinical Trial Summary for Radium-223

Top disease conditions for Radium-223
Top clinical trial sponsors for Radium-223

See all Radium-223 clinical trials

US Patents for Radium-223

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Radium-223 ⤷  Sign Up Substituted thiohydantoin derivatives as androgen receptor antagonists Janssen Pharmaceutica NV (Beerse, BE) ⤷  Sign Up
Radium-223 ⤷  Sign Up Method for the diagnosis, prognosis and treatment of lung cancer metastasis Fundacio Institut de Recerca Biomedica (IRB Barcelona) (Barcelona, ES) Institucio Catalana de Recerca I Estudis Avancats (Barcelona, ES) ⤷  Sign Up
Radium-223 ⤷  Sign Up Antibody drug conjugates (ADCs) with kinesin spindel protein (KSP) BAYER PHARMA AKTIENGESELLSCHAFT (Berlin, DE) ⤷  Sign Up
Radium-223 ⤷  Sign Up Aryl-cyanoguanidine compounds Bayer Pharma Aktiengesellschaft (Berlin, DE) ⤷  Sign Up
Radium-223 ⤷  Sign Up Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors Array BioPharma Inc. (Boulder, CO) ⤷  Sign Up
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Radium-223

Drugname Country Document Number Estimated Expiration Related US Patent
Radium-223 Argentina AR107432 2036-01-11 ⤷  Sign Up
Radium-223 Australia AU2017207268 2036-01-11 ⤷  Sign Up
Radium-223 Australia AU2019203280 2036-01-11 ⤷  Sign Up
Radium-223 Australia AU2021201018 2036-01-11 ⤷  Sign Up
Radium-223 Brazil BR112018014015 2036-01-11 ⤷  Sign Up
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.